|
|
Hectorol® (doxercalciferol capsules and injection) is a vitamin D prohormone indicated for the treatment of secondary hyperparathyroidism (SHPT) in patients with Stage 3 or Stage 4 Chronic Kidney Disease (capsules) and in patients with Chronic Kidney Disease on dialysis (capsules and injection).[1,2]
Only Hectorol® is clinically proven to maintain consistent serum concentrations of vitamin D hormone.[3,4]
Hectorol’s unique prohormone structure and hepatic activation are similar to the body’s natural metabolism of vitamin D.[4]
Activation of vitamin D[4,5]
hec_m_safety_info
Important Treatment Considerations
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 Chronic Kidney Disease (capsules) and in patients with Chronic Kidney Disease on dialysis (capsules and injection). Hectorol is contraindicated in patients with a tendency towards hypercalcemia or current evidence of vitamin D toxicity. Overdosage of any form of vitamin D is dangerous. Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs. Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification. Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia. Magnesium-containing antacids and Hectorol should not be administered concomitantly. Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH. Adverse events reported by ≥ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea, and rhinitis. Adverse events reported by ≥ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus. See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information or call Genzyme Medical Information at 1-800-847-0069.
References
References
1. Hectorol (doxercalciferol capsules) Package Insert, Cambridge, MA: Genzyme Corp.;2008.
2. Hectorol (doxercalciferol injection) Package Insert, Cambridge, MA: Genzyme Corp.;2006.
3. Upton RA, Knutson JC, Bishop CW, et al. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant. 2003;18:750-758.
4. Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogs. Seminars in Dialysis. 2002;15:352-357.
5. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8-F28.
|
|
 |
|
|
|
| Contact |
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email Us
|
 |
|
|
|
|